GNR-051 is under clinical development by Generium and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GNR-051’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GNR-051 overview

GNR-051 is under development for the treatment of metastatic solid tumors including non-small cell lung cancer, metastatic renal cell carcinoma and metastatic melanoma. The drug candidate acts by targeting PD1 (programmed cell death protein 1). It is administered through intravenous route.

Generium overview

Generium is a pharmaceutical company developing novel biological drugs for the treatment of orphan diseases. Generium is headquartered in Moscow, Russia.

For a complete picture of GNR-051’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.